NCT05959720View on ClinicalTrials.gov

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

RecruitingOBSERVATIONAL
Enrollment

180

Participants

Timeline

Start Date

September 5, 2023

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2030

Conditions
Acute Lymphoid LeukemiaMinimal Residual DiseaseGene AbnormalityChemotherapeutic Toxicity
Interventions
DRUG

Prednisone

60 mg/m2 D1 to D21

DRUG

Vincristin

1.5 mg/m2 D1, D8, D15 and D22

DRUG

Daunorubicin

40 mg/m2 D1, D8, D15 and D22

DRUG

Peg-asparaginase

2000 UI/m2 D12 and D26

DRUG

Intrathecal Suspension

MTX 12 mg, Dexamethasone 2 mg, Cytarabine 60 mg D1, D8, D15, D22, D29

DRUG

Cyclophosphamide

1000 mg/m2 D36 and D64

DRUG

Cytarabine

75 mg/m2 D36 to D39, D43 to D46, D50 to D53 and D57 to D60

DRUG

Mercaptopurine

30 mg/m2 D36 to D63 and D1 to D56 of consolidation

DRUG

Methotrexate

3.000 mg/m2 D8, D22, D36 and D50

DRUG

Doxorubicin

30 mg/m2 D1 and D22

Trial Locations (1)

01246000

RECRUITING

Instituto do Cancer do Estado de Sao Paulo, São Paulo

All Listed Sponsors
collaborator

Servier

INDUSTRY

lead

Instituto do Cancer do Estado de São Paulo

OTHER